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Abstract 
Objective  
We have shown that aggregated low density lipoproteins (LDL) is internalised by 
macrophages and oxidised in lysosomes by redox-active iron. We have now investigated 
if the lysosomal oxidation of LDL impairs lysosomal function and if a lysosomotropic 
antioxidant can prevent these alterations. 
Approach and Results 
LDL aggregated by sphingomyelinase (SMase-LDL) caused increased lysosomal lipid 
peroxidation in human monocyte-derived macrophages or THP-1 macrophage-like cells, 
as shown by a fluorescent probe, Foam-LPO. The pH of the lysosomes was increased 
considerably by lysosomal LDL oxidation as shown by Lysosensor Yellow/Blue and 
LysoTracker  Red. SMase-LDL induced senescence-like properties in the cells as shown 
by β-galactosidase staining and levels of p53 and p21. Inflammation plays a key role in 
atherosclerosis. SMase-LDL treatment increased the LPS-induced secretion of TNF-α, IL-
6 and MCP-1. The lysosomotropic antioxidant, cysteamine inhibited all of the above 
changes. 
Conclusions 
Targeting lysosomes with antioxidants, such as cysteamine, to prevent the intralysosomal 
oxidation of LDL might be a novel therapy for atherosclerosis. 
 
Keywords: LDL, macrophages, lysosomes, lipid peroxidation, antioxidants, 
atherosclerosis   
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Introduction 
The presence of lipid-laden macrophage foam cells is a characteristic feature of 
atherosclerosis (1). The foam cells derive the majority of their lipid from uptake of modified 
lipoprotein, such as aggregated or oxidised low density lipoproteins (LDL) (2). Under 
normal conditions, receptor-mediated uptake of lipoproteins trafficks the particles to 
lysosomes, where at an acidic pH, the lysosomal enzymes break down the protein and 
lipid components of LDL to products that can transverse the lysosomal membrane (3). 
Modified LDL is recognised and taken up by receptors on macrophages, however, due to 
a lack of feedback regulation for such uptake, this leads to accumulation of cholesterol in 
these cells (4). 
Studies which examine foam cell formation by the incubation of macrophages with 
modified monomeric LDL (e.g. oxidised LDL) do not fully reflect the in vivo environment, 
as the majority of the LDL in atherosclerotic plaques is found in an aggregated state and 
bound to subendothelial matrix (5, 6).  
There are many mechanisms that might explain how LDL is oxidised in the arterial wall 
(7). Many of these are inhibited strongly by serum or interstitial fluid (8-10), but some, for 
instance oxidation by myeloperoxidase (11), are relatively resistant to inhibition. 
Furthermore, the conventional oxidised LDL hypothesis does not explain why the large 
clinical trials showed no protection by antioxidants, mainly α-tocopherol, against 
cardiovascular disease (12).  
LDL might be nonoxidatively modified and aggregated by enzymes, such as 
sphingomyelinase, lipoprotein lipase, proteases, or secretory phospholipase A2 enzymes, 
in the extracellular space of atherosclerotic lesions (13), rapidly phagocytosed by 
macrophages and delivered to lysosomes, where we hypothesised it might then be 
oxidised (14). In support of this view, we showed that 7 days after taking up LDL 
aggregated by vortexing, macrophages generated ceroid in their lysosomes. Ceroid 
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(lipofuscin) is a polymerised product of lipid oxidation found within foam cells in 
atherosclerotic lesions (15). The oxidation of LDL in lysosomes is catalysed by iron. The 
LDL was shown to be oxidised in lysosomes (14), rather than in culture medium, because 
the medium consisted of Dulbecco’s modified Eagle’s medium, which does not support 
LDL oxidation by cells (8), and contained serum (20% v/v), which strongly inhibits LDL 
oxidation. Also, ‘pulse-chase’ experiments showed that there was an increase in lipid 
peroxidation in the cells in the complete absence of extracellular lipoproteins (14).  
Sphingomyelinase is found in atherosclerotic lesions and has been proposed to be one of 
the key enzymes causing aggregation of LDL in the extracellular space of the lesions (16). 
Aggregation of LDL by sphingomyelinase has been reported to cause a 10 fold increase in 
cholesteryl ester accumulation in macrophages compared to native LDL (17). We have 
shown that human LDL when aggregated with sphingomyelinase is rapidly taken up by 
human macrophages and oxidised inside lysosomes (18). LDL oxidation by iron at 
lysosomal pH is not inhibited effectively by α-tocopherol (19). Cysteamine is a drug which 
accumulates many fold in lysosomes, due to increased protonation of its amine group at 
acidic pH (20). We have shown that cysteamine is able to greatly inhibit LDL oxidation by 
ferrous iron under lysosomal conditions (21) and copper ions (results not shown).  
de Duve’s group showed that cholesterol accumulates in lysosomes in atherosclerotic 
lesions (22). Hoff’s group later showed that oxidised LDL inactivates the lysosomal 
protease cathepsin B at low pH (23), probably because aldehydes on oxidised LDL 
covalently bind to cysteine and histidine residues on cathepsin B (24, 25). This might help 
to explain why oxidised LDL is not degraded efficiently by lysosomes. In addition, 
lysosomal cholesterol and cholesteryl esters derived from oxidised LDL are resistant to 
removal from lysosomes (26). Oxidised cholesteryl ester aldehydes can react with lysine 
residues of proteins and might be involved in ceroid formation (27). Lysosomal 
dysfunction might play an important role in foam cell formation and plaque development 
(28). Cholesterol accumulation in lysosomes inhibits the vacuolar-ATPase proton pump 
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and increases the pH of lysosomes beyond the pH range of lysosomal acid lipase (29). 
Oxidised LDL and cholesterol crystals are able to cause profound lysosomal dysfunction 
in mouse macrophages through disruptions in the pH, proteolytic capacity and membrane 
integrity of these organelles (30).  
Atherosclerosis is also seen to be associated with biological ageing, as atherosclerotic 
plaques show evidence of cellular senescence characterized by reduced cell proliferation, 
apoptosis, elevated DNA damage, epigenetic modifications and telomere dysfunction (31). 
Not only is cellular senescence associated with atherosclerosis, there is growing evidence 
that cellular senescence may promote atherosclerosis (32-34). It is believed that oxidative 
stress-induced damage to cellular components, probably due to the combination of 
increased reactive oxygen species (ROS) and impaired antioxidant defence, is a major 
contributor to the ageing process (35). Although it is well established that oxidised 
lipoproteins and their products are able to induce ROS-dependent senescence in cells 
(36-38), it is not known if the lysosomal oxidation of LDL can induce senescence in human 
cells. 
Inflammation participates in atherosclerosis during initiation and throughout all stages of 
plaque development (39). Expression and secretion of inflammatory cytokines, like TNF-α, 
IL-1β, IL-6 and MCP-1, by the cells in the arterial intima is another characteristic feature of 
atherosclerosis. Many studies have shown that oxidised LDL can activate macrophages, 
including inflammatory reactions (40), but the possible role of lysosomal oxidation of LDL 
is unknown. 
We report here that lysosomal oxidation of aggregated LDL affects the pH of lysosomes in 
human macrophages by altering the lysosomal pH and induces cellular senescence and 
secretion of inflammatory cytokines. These effects were reversed by the lysosomotropic 
antioxidant cysteamine, which we have shown inhibits the oxidation of LDL at lysosomal 
pH and in lysosomes of cultured macrophages (21).  
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Materials and Methods 
Materials and methods 
Chemicals and reagents used in this study were purchased from Sigma-Aldrich, Dorset, 
UK, or Fisher Scientific Ltd, Loughborough, UK, unless otherwise stated. Solutions were 
prepared using ultrapure water generated from a Barnstead Nanopure system. Organic 
solvents were HPLC or molecular biology grades.  
LDL isolation 
Blood was taken from healthy volunteers after overnight fasting using EDTA (final 
concentration 3 mmol/l) as the anticoagulant. LDL (1.019 to 1.063 g/ml) was isolated from 
the plasma by sequential density ultracentrifugation at 4 °C, as described previously (41). 
LDL was stored in the dark at 4 °C and used within 1 month.  
Cell culture 
Human macrophages or THP-1 cells were cultured under humidified 95% air/5% CO2 at 
37 °C in Gibco RPMI 1640 containing L-glutamine (0.3 g/l), penicillin (50 IU/ml), 
streptomycin (50 µg/ml), amphotericin B (0.95 µg/ml) and human or fetal bovine serum 
(10%, v/v), respectively, unless otherwise stated. THP-1 cells were purchased from the 
European Collection of Cell Cultures (Salisbury, UK). THP-1 cells were incubated in 
RPMI-1640 (2 ml per well) containing 10% (v/v) FCS with PMA (25 ng/ml) in 12-well tissue 
culture plates at 1 x 106 cells per well for 72 h to differentiate into macrophages. The 
macrophages were then washed and rested for a further 24 h before treatment with LDL. 
Human monocyte-derived macrophages (HMDM) were prepared from blood donated by 
healthy adults using Lymphoprep™ density gradient solution (Axis-Shield, Oslo, Norway) 
as previously described (42).  Briefly, after separation from blood cells, monocytes were 
incubated in RPMI medium containing 0.05% (v/v) human serum in nonadherent 6-well 
tissue culture plates for 40 h, then transferred to ordinary 6-well tissue culture plates with 
RPMI with 10% (v/v) human serum for 10 to 14 days. 
7 
 
Aggregation of LDL with sphingomyelinase  
Native LDL was diluted to 2 mg protein/ml with a buffer containing NaCl (150 mmol/l), 
MgCl2 (10 mmol/l) and HEPES (5 mmol/l), pH 7.4 and incubated with sphingomyelinase 
from Bacillus cereus (Sigma, catalogue number S9396-25UN) at 10 mU/ml (43), until the 
attenuance (absorbance plus light scattering) at 680 nm increased from about 0.0017 to 
0.027. The sphingomyelinase aggregated-LDL (SMase-LDL) was then dialysed against 
phosphate buffer (NaCl 140 mM, Na2HPO4 8.1 mM, NaH2PO4 1.9 mM and EDTA 100 
µM), pH 7.4, pre-treated with washed Chelex-100 to remove contaminating transition 
metals) (44), and sterilised with a 0.45 µm Minisart filter before use. Aggregation was 
confirmed by dynamic light scattering in UV grade cuvettes with a Zetasizer Nano Series 
particle sizer (Malvern Instruments, Worcestershire, UK). 
Lysosomal lipid peroxidation  
The process of lipid peroxidation in the lysosomes of macrophages was studied by 
employing a fluorescent probe called Foam-LPO, recently synthesised by Zhang et al. 
(45) and kindly provided by Professor Y. Xiao of Dalian University of Technology, PRC. 
Foam-LPO is a BODIPY derivative containing a conjugated diene group within its 
fluorophore structure, which behaves as a lipid peroxidation signalling unit, and a weakly 
alkaline tertiary amino group which enables the probe to be protonated and hence trapped 
and accumulated in the lysosomes. The conjugated diene group degrades in response to 
lipid peroxidation causing a fluorescent spectral shift from 586 nm to 512 nm, which can 
be measured by flow cytometry. THP-1 macrophages or HMDM (1 x 106 cells per well in 
12-well tissue culture plates) were incubated with pre-warmed culture medium (2 ml per 
well) either alone or containing native LDL (200 µg protein/ml) or SMase-LDL (200 µg 
protein/ml) in the presence or absence of cysteamine for 24 h at 37 °C. The adherent 
macrophages were washed three times with pre-warmed PBS and then scraped into 
culture medium using a plastic cell scraper and treated with Foam-LPO (2 µM) in RPMI-
1640 for 15 min and finally analysed using a BD Biosciences C6 flow cytometer. The data 
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were analysed using FlowJo software by determining the mean fluorescence intensity for 
each condition using untreated cells as a control. The fluorescence intensity ratio of the 
green channel to red channel (ratiometry) was taken as a measure of lysosomal lipid 
peroxidation.  
Reactive oxygen species (ROS) detection 
We also looked at the effect of SMase-LDL and cysteamine on the overall oxidative status 
of the macrophages by measuring reactive oxygen species (ROS) using the superoxide 
indicator dihydroethidium (DHE) (46). THP-1 or HMDM (1 x 106 cells per well in 12-well 
tissue culture plates) were incubated with pre-warmed culture media (2 ml per well) either 
alone or containing native LDL (200 µg protein/ml) or SMase-LDL (200 µg protein/ml) in 
the presence or absence of cysteamine for 24 h at 37 °C. The macrophages were there 
scraped off the plates, washed by centrifugation (5 min, 500 g) and treated with DHE (10 
µM) for 30 min. The cells were then washed three times with FACS buffer and analysed 
using a BD Biosciences C6 flow cytometer and analysed using FlowJo software by 
determining the mean fluorescence intensity for each condition using untreated cells as a 
control. 
Assessment of lysosomal function   
The lysosomal function of cells was measured using a lysosomotropic tracking dye called 
LysoTracker® Red DND-99 (Life Technologies), which accumulates in lysosomes due to 
proton trapping (47). THP-1 macrophages or HMDM (1 x 106 cells per well in 12-well 
tissue culture plates) were incubated with pre-warmed culture medium (2 ml per well) 
either alone or containing native LDL (100 µg protein/ml) or SMase-LDL (100 µg 
protein/ml) in the presence or absence of freshly-dissolved cysteamine for 72 h at 37 °C, 
with a change of medium every 24 h. After 72 h, the macrophages were washed three 
times with pre-warmed PBS to remove any residual LDL or cysteamine. The adherent 
macrophages were scraped into culture medium using a plastic cell scraper, collected into 
15 ml sterile polypropylene tubes and centrifuged at 500 x g for 5 min at room 
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temperature to remove cell debris. The cells were resuspended into 200 µl RPMI-1640 
medium (containing 10% (v/v) FCS) each and transferred into a clear 96-well round 
bottom microplate (Greiner CellStar®) and treated with LysoTracker Red (500 nM) in 
RPMI-1640 for 30 min at 37 °C. Cells were washed twice with HBSS, resuspended in 
FACS buffer and analysed using a BD Biosciences C6 flow cytometer. The data analysis 
was done using FlowJo software by determining mean fluorescence intensity for each 
histogram using untreated cells as a control. 
Measurement of lysosomal pH in macrophages 
Measurement of lysosomal pH in THP-1 cells was performed using a ratiometric 
lysosomal pH indicator dye called LysoSensor® Yellow/Blue DND-160 (Invitrogen) (48). 
THP-1 macrophages or HMDM (1 x105 cells per well in 96-well black microplate) were 
incubated with either no LDL or native LDL (100 µg protein/ml) or SMase-LDL (100 µg 
protein/ml) every 24 h for 72 h in the presence or absence of cysteamine. After 72 h, the 
medium containing LDL and cysteamine was washed off with PBS and the macrophages 
were then incubated with 5 µM Lysosensor Yellow/Blue for 30 min at 37 °C under 5% 
CO2. A separate set of THP-1 macrophages or HMDM were used to generate the pH 
calibration curve by a modification of the protocol established by Diwu et al (49). THP-1 
macrophages or HMDM (1 x105 cells per well for 72 h in 96-well black microplate) were 
incubated in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (5 mM NaCl, 115 mM KCl, 
1.3 mM MgSO4, 25 mM MES), with the pH adjusted to a range from 4 - 6.0. Ten min prior 
to the LysoSensor addition, the H+/Na+ ionophore, monensin, and the H+/K+ ionophore, 
nigericin, were added to a final concentration of 10 μM each. This allowed lysosomal pH 
to equilibrate with the MES buffer and facilitated the creation of a standard curve 
correlating pH with the fluorescence emission spectra. Both the plates were read in a 
FLUOstar Optima fluorometer (BMG Labtech), with excitation at 355 nm. The ratio of 
emission 440 nm/535 nm was then calculated for each sample and the pH values were 
determined from the standard plot generated. 
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Cellular senescence  
Detection of senescent cells was done by using the senescence associated β-
galactosidase staining procedure described by Dimri et al (50) and p53/p21 expression 
(51, 52). THP-1 macrophages or HMDM (4,000 per well) were plated in 12-well tissue 
culture plates (Corning). The adherent macrophages were washed three times with pre-
warmed PBS and rested for 24 h. The cells were then incubated in fresh culture medium 
containing either no LDL, native LDL (100 µg protein/ml) or SMase-LDL (100 µg 
protein/ml) every 24 h for 72 h in the presence or absence of freshly-dissolved 
cysteamine. After 72 h, the medium was removed and cells were washed twice in PBS (2 
ml) at room temperature. The cells were then either stained for β-galactosidase activity or 
for the expression of p53 and p21. For β-galactosidase staining cells were fixed for 3 min 
with 500 µl paraformaldehyde (4% w/v) per well at room temperature. The fixative was 
removed and the cells were washed with PBS. Cells were then exposed to 5-bromo-4-
chloro-3-indolyl-D-galactopyranoside (X-gal, pH 6) (50) staining solution (600 µl per well) 
and samples were incubated at 37 °C without CO2 for 18 h. The staining solution was then 
removed and the plates were washed once with deionised water at room temperature and 
then twice with methanol. The plates were allowed to air dry after the last methanol 
passage and the blue stained, senescent, cells were visualised using a Nikon inverted 
phase contrast light microscope, with images taken at 10 magnification. Quantification of 
the blue stained cells was done manually (i.e. a cell was either blue or not) from 5 distinct 
fields of view from each well. For p53 and p21 expression, cells were scrapped from the 
plates and stained with p53 monoclonal antibody (1:100, BP53-12, ThermoFisher), FITC 
and p21 monoclonal antibody (1:200, R.229.6, ThermoFisher) followed by F(ab')2-goat 
anti-rabbit IgG (H+L) secondary antibody, PE-Cyanine5.5 (L43018, ThermoFisher) and 
analysed by flow cytometry.  
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Cytokine secretion 
We looked at the effect of lysosomal oxidation of LDL on secretion of the pro-inflammatory 
cytokines, TNF-α, MCP-1, IL-1β and IL-8 using commercially available ELISA kits. TNF-α 
levels were analysed using the human TNF-α ELISA Ready-SET-Go!® reagent kit 
(eBioscience Cheshire, UK), while MCP-1, IL-1β and IL-8 were measured using ELISA 
MAX™ Deluxe (Biolegend). THP-1 macrophages or HMDM were incubated in fresh 
culture medium alone or with native LDL or SMase-LDL (both at 50 µg protein/ml) for 
either 12 h or 24 h. To study the effect of cysteamine, macrophages were pre-treated with 
different concentrations of freshly-dissolved cysteamine for 24 h prior to LDL addition. 
After incubation with LDL, the medium was removed and the wells were washed three 
times with warm PBS. The washed cells were then treated with fresh culture medium 
containing ultrapure LPS derived from Escherichia coli (10 ng/ml) (Sigma) for 4 h to trigger 
cytokine production (53). The medium from each well was collected and assayed 
immediately using the manufacturer’s instructions. 
Measurement of conjugated dienes 
SMase-LDL (50 µg LDL protein/ml) was oxidised with freshly dissolved FeSO4 (5 µmol/L) 
at 37 °C in a NaCl/sodium acetate buffer (NaCl 150 mmol/l, sodium acetate 10 mmol/L; 
pH 4.5) in capped quartz cuvettes  and conjugated dienes were monitored in the presence 
or absence of cysteamine (25 µm) using a method based on that of Esterbauer et al. (54)  
The change in attenuance at 234 nm was measured at 37 °C against reference cuvettes 
containing all the components except LDL.  Measurements were taken at one minute 
intervals in a Lambda-2 6-cell or a Lambda Bio 40 8-cell spectrophotometer with UV 
Winlab software. 
Loss of LDL-tryptophan fluorescence measurement 
ApoB-100 contains 37 tryptophan residues that give LDL a strong fluorescence at 331 nm 
(Ex 282 nm). On oxidation, the LDL-tryptophan fluorescence decreases continuously 
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indicating the LDL is being oxidised (55). The decrease in tryptophan fluorescence was 
measured on a Cary Eclipse fluorescence spectrophotometer using the time-drive method 
at an emission wavelength of 331 nm, with excitation set at 282 nm.(55) The emission and 
excitation slits were set at 10 nm to obtain optimal fluorescence output. LDL (50 µg LDL 
protein/ml) was oxidised by freshly dissolved FeSO4 (5 µmol/L) at 37 °C in the 
NaCl/sodium acetate buffer, pH 4.5 in capped quartz cuvettes with or without cysteamine 
and the tryptophan fluorescence was measured every 10 min. 
Statistical analysis 
Unless stated otherwise, all results are expressed as means ± the standard error of the 
mean (S.E.M) of pooled data from 3 to 5 experiments as specified in the figure legends. 
Comparison of two means was done using a 2-tailed unpaired Student’s t test. For 
comparing more than two means one-way ANOVA was used followed by Tukey’s post 
hoc analysis to measure the level of statistical significance between groups. The level of 
significance of difference is indicated in the graphs as follows: * p ≤ 0.05, ** p ≤ 0.01, and 
*** p ≤ 0.001. ANOVA and post hoc analyses were carried out with GraphPad Prism 4 
software (La Jolla, CA). A p value of <0.05 was taken to be a statistically significant 
difference.  
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Results 
Macrophages treated with SMase-LDL show increased lysosomal lipid peroxidation 
which is inhibited by cysteamine 
Non-enzymatic oxidation of LDL is considered to be a free radical-driven lipid peroxidation 
chain reaction (56) and therefore lipid peroxidation might be one of the major pathological 
mechanisms involved in atherosclerosis. Lysosomal lipid peroxidation was quantified in 
macrophages using the novel probe Foam-LPO (45). THP-1 macrophage-like cells or 
HMDM were treated with SMase-LDL showed decreased fluorescence intensity in the red 
channel during flow cytometry compared to control macrophages (Figure 1A), showing 
lipid peroxidation was taking place in the lysosomes. Cysteamine (10 µM or 25 µM) 
significantly decreased (but not complete decrease) the red cannel fluorescence with 
SMase-LDL (Figure 1B). The process of lipid peroxidation was quantified by ratiometric 
analysis of the fluorescence intensities of the green and red channels (Figure 1C) (45). 
The macrophages which were treated with SMase-LDL showed a significant increase in 
the lipid peroxidation levels compared to control macrophages. The lysosomotropic 
antioxidant, cysteamine (10 µM or 25 µM), reduced lipid peroxidation in the SMase-LDL 
treated macrophages in a concentration-dependent manner. Cysteamine on its own had 
no significant effect on lipid peroxidation.  
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Macrophages treated with SMase-LDL show increased ROS production which is 
inhibited by cysteamine 
We looked at the overall oxidative status of the HMDM by using dihydroethidium (DHE), 
which detects superoxide and hydrogen peroxide. The macrophages which were treated 
with SMase-LDL showed increased ROS production compared to the control (Figure 1E) 
and native LDL treated macrophages (Figure 1F). Cysteamine prevented the increase in 
ROS production in the macrophages which were treated with SMase-LDL (Figure 1G) 
back to control levels in a concentration-dependent manner (Figure 1H). Cysteamine on 
its own showed no marked effect on the total oxidative status of the macrophages (Figure 
1H). 
Lysosomal oxidation of SMase-LDL increases the lysosomal pH in macrophages 
Having shown that SMase-LDL increased lysosomal lipid peroxidation, we investigated 
the accumulation of lysosomotropic dye LysoTracker Red in macrophages. Native LDL-
treated THP-1 cells showed a non-significant 6 ± 4 % decrease in LysoTracker Red signal 
after 72 h compared to the control cells, whereas macrophages treated with SMase-LDL 
showed a significant decrease of 26 ± 2% (p<0.001) in the signal compared to the control 
cells (Figure 2 A,B &C). In HMDM, native LDL caused a significant 21 ± 4% (p<0.01) 
decrease in LysoTracker Red signal compared to untreated cells whereas in the cells 
treated with SMase-LDL there was a 32 ± 2% (p<0.001) loss in signal compared to the 
control cells (Figure 2D). The loss in signal due to SMase-LDL was largely reversed by 25 
µM cysteamine in both the cell types (Figure 2 C & D). Furthermore, cysteamine on its 
own did not have any significant effect on LysoTracker Red accumulation (Figure S1). We 
next investigated if the decreased uptake of LysoTracker Red was due to a change in the 
pH of the lysosomes.   
Native LDL did not significantly increase the acidic pH of the lysosomes (Figure 3A & D). 
Treatment of THP-1 cells and HMDM with SMase-LDL for 72 h significantly increased the 
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lysosomal pH to 6.2 ± 0.2 in THP-1 macrophages and to 6.3 ± 0.6 in HMDM. Cysteamine 
treatment (10 µM or 25 µM) prevented the SMase-LDL induced increase in lysosomal pH 
in both types of cells (Figure 3 A & D). To determine if the effect of cysteamine on 
lysosomal pH was due to inhibition of lysosomal oxidation of LDL or due to a direct effect 
on lysosomal pH, the effect of cysteamine was assessed in untreated or native LDL-
treated THP-1 macrophages. Treatment with 10 µM or 25 µM cysteamine had no 
significant effect on the lysosomal pH in either case (Figure 3B and C). Also, cysteamine 
(10 µM or 25 µM) did not have any significant effect on HMDM on its own (Figure 3E). 
Lysosomal oxidation of SMase-LDL induces senescence in macrophages 
As cell senescence might be important in atherosclerosis (33), we investigated the effect 
of lysosomal LDL oxidation on the lysosomal senescence-associated β-galactosidase 
assay and the expression p21 and p53 proteins. Incubation of THP-1 cells or HMDM with 
native LDL and especially SMase-LDL increased the senescence-associated β-
galactosidase activity in their lysosomes (Figure 4 A-F and S2). Cysteamine (10 µM) 
treatment reduced its activity substantially. We then looked at the expression of two other 
senescent markers p53 and p21 in HMDM and found that treatment with SMase-LDL 
significantly increased these markers compared to untreated control cells, while treatment 
with cysteamine significantly reduced the SMase-LDL induced expression of both of these 
markers (Figure 4 G-J). Cysteamine on its own had no effect on p53 or p21 expression.  
Lysosomal oxidation of SMase-LDL leads to increased secretion of pro-
inflammatory cytokines  
Inflammation, in addition to cell senescence, is important in atherosclerosis (39). We 
therefore investigated if the lysosomal oxidation of LDL might cause an increase in 
secretion of inflammatory cytokines. THP-1 macrophages showed a significant increase in 
LPS stimulated TNF-α secretion after both 12 and 24 h incubation with native LDL and 
more so with SMase-LDL (Figure 5A). Secretion of TNF-α tended to increase, but not 
significantly, from 12 h to 24 h with native and SMase-LDL treatment, but decreased in the 
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control cells which received no LPS. In HMDM, there was a large increase in TNF-α 
secretion when treated with SMase-LDL for 24 h, whereas native LDL had no significant 
effect (Figure 5B). Prior treatment with cysteamine for 24 h reduced the secretion of TNF-
α by the macrophages incubated with SMase-LDL in a concentration dependent way, 
suggesting that the increased secretion seen with SMase-LDL was due to the lysosomal 
oxidation of LDL. Furthermore, cysteamine on its own did not have any effect on LPS- 
induced TNF-α secretion in HMDM. Similar effects of SMase-LDL and cysteamine were 
seen for IL-6, IL-1β and MCP-1 secretion (Figure 5 C-G).   
Cysteamine inhibits LDL oxidation by iron at lysosomal pH 
We have previously shown that catalytically active iron within the lysosomes causes LDL 
oxidation. Cysteamine (25 µM) completely inhibited the initial oxidation of SMase-LDL by 
ferroud iorn in vitro in a spectrophotometer and caused a significant increase in the lag 
phase at pH 4.5 (Figure 6A). The time taken for SMase-LDL to reach an attenuance of 0.1 
during oxidation catalysed by iron was 76 ± 3 min when no cysteamine was added, 
compared with 352 ± 5 min in the presence of cysteamine (p<0.001, n=3), which is a 5 ± 
0.2 fold inhibition of LDL oxidation (Figure 6B). Incubation of SMase-LDL with ferrous 
sulphate leads to continuous loss of tryptophan fluorescence, with a sharp loss initially 
(Figure 6C). Cysteamine (25 µM) significantly prevented the loss of LDL-tryptophan 
fluorescence for 500 ± 50 min. The LDL fluorescence decreased by 34 ± 3% after 150 min 
of LDL oxidation with ferrous iron, whereas in the presence of cysteamine the 
fluorescence decreased by only 2 ± 0.9% (p<0.001, n =5) (Figure 6D). 
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Discussion 
The lysosomal cholesteryl esterase and proteases that degrade LDL are normally active at 
about pH 4.5 (57, 58). A change in lysosomal pH can cause lysosomal dysfunction (59). 
Lysosomes generate and maintain their pH gradients by using the activity of a proton-
pumping V-type ATPase, which uses the metabolic energy of ATP to pump protons into the 
lysosome lumen (60). The lysosome receives extracellular cargo (via endocytosis) and 
cytoplasmic material (via autophagy) for degradation (61). Failure of the lysosome to 
process its contents efficiently leads to an accumulation of undigested material inside the 
lumen and can cause lysosomal dysfunction (62).  
The accumulation of lysosomal free cholesterol has been shown to directly cause an 
increase in lysosomal membrane cholesterol content (29). The data presented here have 
shown that treatment of human macrophages with SMase-LDL for 3 days decreased 
LysoTracker Red accumulation (Figure 2). The lysosomotropic antioxidant, cysteamine, 
attenuated this loss. The decrease in Lysotracker Red accumulation was probably due to an 
increase in lysosomal pH. SMase-LDL treatment for 72 h increased the lysosomal pH of the 
THP-1 macrophages considerably from 4.9 to 6.2 (which represents a decrease in hydrogen 
ion concentration of 20 times), compared to the pH of untreated cells and from 3.2 to 6.3 in 
HMDM, a decrease in hydrogen ion concentration of 1,250 times (Figure 3D). The increase 
in pH would be expected to decrease substantially the degradation of endocytosed LDL (57, 
58) and lead to more lipid accumulation in lysosomes and thus more lipid-laden foam cells. 
Cysteamine prevented the SMase-LDL induced increase in lysosomal pH, but had no great 
effect on the lysosomal pH of macrophages in the absence of LDL or in the presence of 
native LDL. Importantly, this suggests that the increase in lysosomal pH in the presence of 
SMase-LDL was due to the lysosomal oxidation of this LDL, possibly due to lipid 
peroxidation products such as 7-ketocholesterol, 4-hydroxynonenal or malondialdehyde 
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which have previously been shown to inhibit the activity of the lysosomal V-ATPase causing 
lysosomal dysfunction (29, 63, 64).  
We found that both THP-1 and HMDM macrophages that were treated with SMase-LDL had 
increased lipid peroxidation levels in their lysosomes and co-treatment with cysteamine 
reduced the lysosomal lipid peroxidation in a concentration dependent manner (Figure 1A-
D). Furthermore, we found that SMase-LDL treated HMDM had higher ROS levels compared 
to control and native LDL treated macrophages and cysteamine considerably reduced the 
ROS levels. We have recently proposed that hydroperoxyl radicals (protonated superoxide 
radicals, HO2●) are the main species in the lysosomes of macrophages that can oxidise LDL 
(65) and these might possibly be responsible for the increased ROS in the presence of 
SMase-LDL.  
There is strong evidence suggesting that decreased lysosomal proteolytic activity and 
increased lysosomal pH occurs as a consequence of aging in long-lived post mitotic cells 
(66-68). In fact, increasing lysosomal function is being considered as a plausible avenue for 
anti-ageing interventions so as to increase the longevity of cells (69). It has been proposed 
that oxidative stress-induced damage to cellular components, probably due to the 
combination of higher levels of reactive oxygen species (ROS) and impaired antioxidant 
defence, is the main contributor to the ageing process (35). The accumulation of oxidation 
products of cholesterol (oxysterols) has been seen to induce senescence in human cells, 
through the generation of reactive oxygen species (69, 70). Native LDL and especially 
SMase-LDL treatment for 3 days induced senescence in human macrophages (Figure 4) 
and treatment with cysteamine significantly decreased the senescence induced by SMase-
LDL, suggesting that the senescence was due to lysosomal oxidation of SMase-LDL (and 
native LDL). The significance of this is uncertain, however, as macrophages in vivo (unlike 
the tumour cell line THP-1 macrophages) are not considered to be long lived cells.   
19 
 
Inflammation plays a key role in the initiation, progression and rupture of atherosclerotic 
lesions (71). Both minimally oxidised LDL and more highly oxidised LDL cause the secretion 
of proinflammatory cytokines by macrophages (72, 73) by activating toll-like receptor-4 (TLR-
4). Some studies have shown, however, that oxidised LDL inhibits the production of 
inflammatory cytokines by macrophages in response to inflammatory stimuli, such as 
lipopolysaccharide (LPS) (74). The effect of vortexed and acetylated LDL on the expression 
of the proinflammatory cytokine, TNF-α, is controversial with some reports showing a 
decrease in its levels (75, 76) and others showing an increase (77). LPS is considered a 
classical ligand of TLR4 receptors (78). We sought to determine whether lysosomal 
oxidation of SMase-LDL by human macrophages, could alter the secretion of 
proinflammatory cytokines (TNF-α, IL-1β, IL-6 and MCP1). Both native LDL and to a greater 
extent SMase-LDL increased the LPS-induced secretion of all the cytokines (Figure 5). The 
potentiation of LPS-induced TNF-α secretion by native LDL is in agreement with the 
previous studies by Netea et al (79). Pre-incubation with cysteamine decreased the 
secretion of these proinflammatory cytokines by macrophages incubated with SMase-LDL, 
suggesting that some of the secretion was due to the lysosomal oxidation of LDL. The 
reduction by cysteamine was sometimes only partial probably because LPS was directly 
stimulating cytokine secretion. The increased secretion of proinflammatory cytokines by 
native and SMase-LDL might possibly be due to the oxidative stress caused by the 
lysosomal oxidation of LDL (80), but the exact mechanism needs detailed investigation. 
In conclusion, we have shown that the lysosomal oxidation of LDL alters the function of 
macrophages in potentially atherogenic ways, namely an increase in lysosomal pH, cell 
senescence and proinflammatory cytokine secretion. These effects can be inhibited by the 
lysosomotropic antioxidant, cysteamine, suggesting a novel therapeutic approach to treat 
atherosclerosis. 
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Figure 1 Lipid peroxidation and ROS in human macrophages  
THP1 macrophages or HMDM were treated with no LDL, native LDL or SMase-LDL (both at 
200 µg protein/ml LDL protein) in the presence or absence of 5 µM, 10 µM or 25 µM 
cysteamine for 24 h. The cells were then incubated with either 2 µM Foam-LPO for 15 min or 
10 µM DHE for 30 min, harvested and assayed by flow cytometry. (A) Mean fluorescence 
intensity of (MFI) of Foam-LPO in red channel of healthy THP-1 macrophages, native-LDL 
treated and SMase-LDL treated THP-1 macrophage. (B) MFI of Foam-LPO in red channel of 
SMase-LDL treated THP-1 macrophages in presence of absence of cysteamine 10 µM and 
25 µM. (C) & (D) Show lipid peroxidation calculated from the ratio between the mean 
fluorescence intensity of the green channel (FL1) and red (FL3) channel in THP-1 
macrophages and HMDM, respectively. (E) and (F) show overall ROS production in HMDM 
control, native and SMase-LDL treated cells. (G) shows the effect of cysteamine (25 µM) on 
SMase-LDL ROS production. (H) Analysis of MFI of ROS generation  
 (*** p<0.001, (** p<0.01 compared to untreated cells, ### p<0.001, ## p<0.01, # p<0.05, 
ANOVA followed by Tukey’s test, n=3-6 independent experiments).  
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Figure 2 Effect of SMase-LDL and cysteamine on LysoTracker Red accumulation by 
macrophages 
THP-1 macrophages or HMDM (1 x 10
6
) were cultured in 12 well tissue culture plates in 
RPMI medium (containing 10%  v/v FCS) alone or containing native LDL or SMase-LDL with 
or without cysteamine (10 µM or 25 µM) for 72 h. All LDL concentrations were 100 µg 
protein/ml. After 72 h, cells were treated with 500 nM LysoTracker Red for 30 min and then 
assayed by flow cytometry. Mean fluorescence intensity peak of LysoTracker Red in the red 
channel was then measured. (A) Mean fluorescence intensity (MFI) in red channel of healthy 
THP-1 macrophages, native-LDL treated and SMase-LDL treated macrophage. (B) MFI in 
red channel of SMase-LDL treated THP-1 macrophages in presence of absence of 
cysteamine 10 µM and 25 µM. (C) data expressed as percentage loss of mean fluorescence 
intensity of LysoTracker Red in the red channel compared to untreated control macrophages 
in THP-1 macrophages. (D) Data expressed as percentage loss of mean fluorescence 
intensity of LysoTracker Red in the red channel compared to untreated macrophages in 
HMDM.  (** p<0.01, *** p<0.001 compared with untreated cells, 
##
 p<0.01, 
### 
p<0.001 
compared with SMase-LDL treated cells, ANOVA followed by Tukey’s test, n = 4 
independent experiments). 
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 Figure 3 Effect of lysosomal oxidation of SMase-LDL on the pH of lysosomes in THP-1 
macrophages.  
 THP-1 macrophages (A) or HMDM (D) were cultured in a black 96-well microplate at 1 
x 105 per well in RPMI medium (containing 10% v/v FCS) with no LDL, native LDL  or 
SMase-LDL (both at 100 µg protein/ml) with or without cysteamine (Cyst) (10 µM or 25 
µM) for 72 h. The cells were then treated with 5 µM Lysosensor Yellow/Blue for 30 min 
at 37°C. The samples were then read in a FLUOstar Optima fluorometer, with 
excitation at 355 nm. The ratio of emission at 440 nm and 535 nm was then calculated 
for each sample and the pH values determined from a standard plot. (B) & (E) show 
effect of cysteamine on control THP-1 and HMDM respectively, (C) shows effect of 
cysteamine on native LDL treated THP-1 cells (* p<0.05, ** p<0.01 and *** p<0.001 
compared to SMase-LDL treated macrophages, ANOVA followed by Tukey’s test of at 
least 4 independent experiments). 
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 Figure 4 Effect of lysosomal oxidation of LDL on senescence in human 
macrophages 
 HMDM macrophages were cultured in 12 well tissue culture plates at 3000 cells per 
well in RPMI medium (containing 10% v/v lipoprotein-deficient serum) containing either 
no LDL (A), native LDL (B), SMase-LDL alone (C) or SMase-LDL (all at 100 µg 
protein/ml) with 10 µM cysteamine (D) for 72 h. The cells were then stained to identify 
any senescent cells by a lysosomal β-galactosidase activity assay and p53 and p21 
expression. (E) and (F) show the percentage of senescent cells in HMDM 
macrophages and THP-1 cells, which had been treated in the same way, respectively. 
The images shown are representative of three independent experiments.  
 (G) and (H) show the mean fluorescence intensity (MFI) for p53 and p21 expression in 
HMDM. (I) and (J) shows a comparison of p53 and p21 MFI under various treatment 
conditions. (* p<0.05, ** p<0.01 and *** p<0.001 compared to the control cells, # 
p<0.05, ## p<0.01 and ###p<0.001 for the indicated comparison, ANOVA followed by 
Tukey’s test of at least 3 independent experiments). 
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 Figure 5 Effect of SMase-LDL on cytokine expression in macrophages 
 THP-1 macrophages or HMDM were incubated in fresh RPMI-1640 medium 
(containing 10% v/v FBS), alone or with native LDL or SMase-LDL (both at 50 µg 
protein/ml) for either 12 h or 24 h and the medium assayed for various pro-
inflammatory cytokines. Some of wells were pre-incubated with cysteamine (10 µM or 
25 µM) for 24 h prior to SMase-LDL treatment. After SMase-LDL treatment, the cells 
were washed with PBS and then stimulated with LPS (10 ng/ml) for 4 h at 37 °C and 
the medium was collected and assayed for cytokine levels. 
 (* p<0.05, **p<0. 01, and *** p<0.001 compared to the control cells; # p<0.05, ## p<0.01 
and ###p<0.001 for the indicated comparison. The data shown are from at least 3 
independent experiments and analysed by one-way ANOVA followed by Tukey’s post-
test.  
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Figure 6 Effect of cysteamine on LDL oxidation catalysed by iron at pH 4.5 
SMase-LDL (50 µg protein/ml) in NaCl/sodium acetate buffer (pH 4.5) was incubated with 5 
µM FeSO4 in the presence or absence of cysteamine (25 µM) at 37°C in capped quartz 
cuvettes. Oxidation was monitored by measuring the change in attenuance at 234 nm (A) or 
loss of LDL-tryptophan fluorescence against appropriate reference cuvettes (C). This is a 
representative example of three independent experiments. (B) Time taken to reach an 
attenuance of 0.1 during the oxidation with iron. (D) shows decrease in LDL-tryptophan 
fluorescence after 150 min of oxidation (*** indicates p<0.001, t-test, n = 3 independent 
experiments.  
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 Supplemental Figure S1 Effect of cysteamine on lysosomal function  
 
 HMDM (1 x 106) were cultured in 12 well tissue culture plates in RPMI medium (containing 
10% v/v FCS) with cysteamine (10 µM or 25 µM) for 72 h. The cells were then washed and treated 
with 500 nM Lysotracker Red for 30 min and then assayed by flow cytometry. Mean fluorescence 
intensity peak of Lysotracker Red in the red channel was then measured. Mean of 3 independent 
experiments. 
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  Supplemental Figure S2 Effect of lysosomal oxidation of LDL on senescence in THP-1 macrophages 
THP-1 cells were cultured in 12 well tissue culture plates at 3000 cells per well in RPMI medium 
(containing 10% v/v lipoprotein-deficient serum) containing either no LDL (A), native LDL (B), SMase-
LDL alone (C) or SMase-LDL (all at 100 µg protein/ml) with 10 µM cysteamine (D) for 72 h. The cells 
were then stained to identify any senescent cells by a lysosomal β-galactosidase activity assay. The 
images shown are representative of three independent experiments. 
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